All studies
Nephrology · Biobank · United Kingdom

Xu 2026

Hyperuricemia

ITTSuperiorityAcademia2/5 disclosures
Comparisons
1
In the analysis
1
all comparisons pooled
Target trials
1
Emulations reported
1
2 treatments

Comparisons

1 shown
Randomized trialEmulation
Outcome & target trialTrial vs emulationOn a shared scaleAgreement
Change in serum urate, mg/dL
vs Six randomized losartan trials·MD·Efficacy
-0.29-0.46–-0.12
-0.35-0.66–-0.03
overlapMajor deviation-0.33 SE apart

Design and methods

Estimand
ITT
Design hypothesis
Superiority
Matching / weighting
1:4 genetic matching
Analysis method
G-computation linear regression
Missing data
Complete case
DAG
No
QBA
No

Data and sample

Data type
Biobank
Data sources
1
Geography
United Kingdom
Eligible sample
115
Treated
23
Control
92
Emulations
1
Treatments compared
2

Transparency

2/5
Protocol
No pre-registration
Preprint
No preprint
Data availability
Unavailable
Code availability
Unavailable
Conflicts of interest
Declared: None
Funding
Declared: Public
Funders
British Heart Foundation and NIHR support

The 0-5 count records which disclosures are present. It is not a quality score: a data link does not establish that the data are reusable.

Provenance

Review key
2026_Xu_Losartan
DOI
10.1038/s41440-026-02719-0
Affiliations
University of Manchester and UK Biobank collaborators
Sector
Academia
Target trials (study level)
Six randomized losartan trials